Could Exelixis’ Zanzalitnib Become a $5B Blockbuster?
Exelixis’ near-term outlook hinges on Zanzalitnib: approval and commercial adoption will largely determine the stock’s trajectory.
Cabometics exclusivity extended to 2031 reduces immediate risk, but Zanzalitnib is the binary catalyst investors must watch.
– Patent and legal wins extended Cabometics exclusivity to 2031 and why that matters for near-term stability.
– How Zanzalitnib’s shorter half-life could affect tolerability and enable combination regimens.
– The FDA decision timeline and why approval would materially impact revenue and valuation.
– Company fundamentals: ~31% trailing ROE, strong cash flow, negligible debt, and heavy R&D reinvestment.
– Management track record under CEO Michael Morse and modest succession considerations.
– What investors should monitor: FDA filing, early launch uptake, toxicity and combination data, and Cabometics revenue trends.
————————————————————————
This video is brought to you by The Motley Fool.
Visit https://fool.com/Invest to get access to this special offer. The Motley Fool Stock Advisor returns are 884% as of 3/30/2026 and measured against the S&P 500 returns of 179% as of 3/30/2026. Past performance is not an indicator of future results. All investing involves a risk of loss. Individual investment results may vary, not all Motley Fool Stock Advisor picks have performed as well.
————————————————————————
